List of Tables
Table 1: Stage Definitions for Colorectal Cancer
Table 2: Symptoms of CRC
Table 3: Prognosis for Colon and Rectal Cancer
Table 4: Risk Factors and Comorbidities For CRC
Table 5: 8MM, Five-Year Relative Survival (%)
Table 6: 8MM, Sources Used to Forecast the Diagnosed Incidence of CRC
Table 7: 8MM, Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases of CRC
Table 8: 8MM, Sources of CRC Cancer Stage at Diagnosis
Table 9: 8MM, Sources of Genetic Mutations
Table 10: 8MM, Diagnosed Incident Cases of CRC (N), Both Sexes, Ages ≥18 Years, 2015–2025
Table 11: 8MM, Age-Specific Diagnosed Incident Cases of CRC (N), Both Sexes, Row (%), 2015
Table 12: 8MM, Sex-Specific Diagnosed Incident Cases of CRC (N), Ages ≥18 Years, Row (%), 2015
Table 13: 8MM, Diagnosed Incident Cases of CRC by Cancer Stage at Diagnosis (N), Ages ≥18 Years, Row (%), 2015
Table 14: 8MM, Diagnosed Incident Cases of CRC by Type of Genetic Mutation (N), Both Sexes, Ages ≥18 Years, 2015
Table 15: 8MM, Five-Year Diagnosed Prevalent Cases of CRC (N), Both Sexes, Ages ≥18 Years, 2015–2025
Table 16: Treatment Guidelines for CRC
Table 17: Most Prescribed Neoadjuvant/Adjuvant Regimens for Early-Stage Colon and Rectal Cancer in the 8MM, 2016
Table 18: Most Prescribed Targeted Therapies for mCRC, by Segment in the 8MM, 2016
Table 19: Country Profile – US
Table 20: Country Profile – France
Table 21: Country Profile – Germany
Table 22: Country Profile – Italy
Table 23: Country Profile – Spain
Table 24: Country Profile – UK
Table 25: Country Profile – Japan
Table 26: Country Profile – China
Table 27: Leading Treatments for CRC, 2016
Table 28: Product Profile — Avastin
Table 29: Summary of the Results from the AVF2107 Trial of Avastin Plus IFL
Table 30: Summary of the Results from the CALGB 80405 and FIRE-3 Trials of Avastin/Erbitux plus Chemotherapy
Table 31: Summary of the Results of the ML18147 Study
Table 32: Summary of the Results from the E3200 Trial of Avastin Plus FOLFOX
Table 33: Summary of AEs from the AVF21070 trial of Avastin
Table 34: Avastin SWOT Analysis, 2016
Table 35: Product Profile – Zaltrap
Table 36: Summary of the Results from the VELOUR Study
Table 37: Summary of Frequent Grade 3 and 4 AEs from the VELOUR trial of Zaltrap
Table 38: Zaltrap SWOT Analysis, 2016
Table 39: Product Profile – Cyramza
Table 40: Summary of the Phase III RAISE Trial of Cyramza
Table 41: Summary of Frequent Grade 3 and 4 AEs in a Phase III Trial for Cyramza
Table 42: Cyramza SWOT Analysis, 2016
Table 43: Product Profile — Erbitux
Table 44: Summary of the Result of the CRYSTAL Study
Table 45: Summary of the Results of the CRYSTAL Study – BRAF Mutation
Table 46: Retrospective Analysis of CRYSTAL and FIRE-3 Studies of Erbitux
Table 47: Summary of Frequent AEs from the CRYSTAL Trial of Erbitux
Table 48: Erbitux SWOT Analysis, 2016
Table 49: Product Profile – Vectibix
Table 50: Summary of the Results from the PRIME Trial of Vectibix
Table 51: Summary of the Results from the PEAK Study of Vectibix
Table 52: Summary of the Results from the Phase III Study of Vectibix as Monotherapy
Table 53: Summary of the Results from the ASPECCT Study of Vectibix
Table 54: Incidence of Grade 3–4 AEs of the PRIME Trial of Vectibix
Table 55: Vectibix SWOT Analysis, 2016
Table 56: Product Profile – Stivarga
Table 57: Summary of the Results from the CORRECT Study of Stivarga
Table 58: Summary of Frequent Grade 3 and 4 AEs from the CORRECT Trial of Stivarga
Table 59: Stivarga SWOT Analysis, 2016
Table 60: Product Profile – Lonsurf
Table 61: Summary of the Phase III RECOURSE Trial of Lonsurf
Table 62: Summary of the AEs in the Phase III Trial of Lonsurf
Table 63: Lonsurf SWOT Analysis, 2016
Table 64: Product Profile – TS-1
Table 65: Summary of a Phase III trial of TS-1
Table 66: Summary of Most Common AEs in a Phase III Trial of TS-1
Table 67: TS-1 SWOT Analysis, 2016
Table 68: Unmet Needs and Opportunities in CRC
Table 69: Product Profile – Lefitolimod
Table 70: Summary of the IMPACT Trial of Lefitolimod
Table 71: Summary of the Most Common AEs Reported in the IMPACT Trial of Lefitolimod
Table 72: Lefitolimod SWOT Analysis, 2016
Table 73: Product Profile – Keytruda
Table 74 Summary of the Results of the Phase II Trial of Keytruda
Table 75: Summary of Frequent AEs in the Phase II Trial of Keytruda
Table 76: Keytruda SWOT analysis, 2016
Table 77: Product Profile – Tecentriq
Table 78: Summary of the Phase Ib Trial of Tecentriq
Table 79: Summary of Frequent AEs in the Phase Ib Trial of Tecentriq
Table 80: Tecentriq SWOT analysis, 2016
Table 81: Product Profile – Encorafenib +Binimetinib
Table 82: Summary of the Results from the Phase II Trial of Encorafenib
Table 83: Summary of Frequent AEs in the Phase II Trial of Encorafenib
Table 84: Encorafenib + Binimetinib – SWOT Table, 2016
Table 85: Product Profile – Napabucasin
Table 86: Summary of the Result from the Phase Ib Trial of Napabucasin
Table 87: Summary of the Result from the Phase II Trial Investigating Napabucasin + Vectibix
Table 88: Napabucasin, SWOT Analysis, 2016
Table 89: Product Profile – Vargatef
Table 90: Summary of the Results of the Phase III LUME Colon-1 Trial of Vargatef
Table 91: Vargatef SWOT Analysis, 2016
Table 92: Product Profile – Masitinib
Table 93: Summary of the Results of the Phase II Trial of Masitinib
Table 94: Masitinib SWOT Analysis, 2016
Table 95: Product Profile – Fruquintinib
Table 96: Summary of the Results of the Phase II Trial of Fruquintinib
Table 97: Summary of Frequent AEs in the Phase II Trial of Fruquintinib
Table 98: Fruquintinib SWOT Analysis, 2016
Table 99: Product Profile – Famitinib
Table 100: Summary of the Results of the Phase II Trial of Famitinib
Table 101: Summary of Frequent AEs in a Phase II trial of Famitinib
Table 102: Famitinib SWOT Analysis, 2016
Table 103: Product Profile – Donafenib
Table 104:Donafenib SWOT Analysis, 2016
Table 105: Promising Strategies to Overcome VEGF Resistance
Table 106: Early-stage Strategies for BRAF Mutation-Positive CRC
Table 107: Early-Stage Strategies for KRAS Mutation-Positive CRC
Table 108: Early-Stage Strategies for EGFR Acquired Resistance
Table 109: Anti-PD1 and Anti-PDL1 Drugs in Early-Stage Development for CRC
Table 110: CAR-T Cell Therapies Under Development
Table 111: Vaccines in Development for CRC
Table 112: Radioembolization Techniques Evaluated for the Treatment of CRC Liver Metastasis
Table 113: List of Bevacizumab Biosimilars in Phase III Development
Table 114: Key Companies in the CRC Market in the 8MM, 2015–2025
Table 115: Amgen’s CRC Portfolio Assessment, 2016
Table 116: Bayer’s CRC Portfolio Assessment, 2016
Table 117: Eli Lilly’s CRC Portfolio Assessment, 2016
Table 118: Merck KGaA’s CRC Portfolio Assessment, 2016
Table 119: Merck & Co.’s CRC Portfolio Assessment, 2016
Table 120: Roche’s CRC Portfolio Assessment, 2016
Table 121: Taiho’s CRC Portfolio Assessment, 2016
Table 122: CRC Market Drivers and Barriers, 2016
Table 123: Key Events Impacting Sales for CRC in the US, 2015–2025
Table 124: US CRC Market Drivers and Barriers, 2016
Table 125: Key Events Impacting Sales for CRC in the 5EU, 2015–2025
Table 126: 5EU CRC Market Drivers and Barriers, 2016
Table 127: Key Events Impacting Sales for CRC in Japan, 2015–2025
Table 128: Japan CRC Market – Drivers and Barriers, 2016
Table 129: Key Events Impacting Sales for CRC in China, 2015–2025
Table 130: China CRC Market – Drivers and Barriers, 2016
Table 131: Key Historical and Projected Launch Dates for Colorectal Cancer
Table 132: Key Historical and Projected Patent Expiry Dates for Colorectal Cancer
Table 133 Average Body Weight and Surface Area Across the 8MM
Table 134: Treatment Duration in Colorectal Cancer
Table 135: Average Cost of Therapy of Avastin in the 8MM
Table 136: Average Cost per Cycle of Chemotherapy Regimens in the 8MM
Table 137: Average Cost of Therapy of Cyramza in the 8MM (excluding urban China)
Table 138: Average Cost of Therapy of Erbitux in the 8MM
Table 139: Average Cost of Therapy of Lonsurf in the 8MM
Table 140: Average Cost of Therapy of Stivarga in the 8MM
Table 141: Average Cost of Therapy of Vectibix in the 8MM
Table 142: Average Cost of Therapy of Zaltrap in the US and 5EU
Table 143: High-Prescribing Physicians (non-KOLs) Surveyed, By Country